Simvastatin
| Evidence Level: L1 | Predicted Indications: 8 |
Table of Contents
Simvastatin: From Lipid-Lowering Therapy to Familial Hypercholesterolemia
One-Sentence Summary
Simvastatin is a statin (HMG-CoA reductase inhibitor) used to lower LDL cholesterol. The TxGNN model predicts it may be effective for familial hypercholesterolemia, and the record shows 19 clinical trials and 18 publications on this direction. Heterozygous familial hypercholesterolemia is already a labelled use of simvastatin, so this is best read as confirmation of an established use rather than a novel repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the supplied registration records; simvastatin is a lipid-lowering statin |
| Predicted New Indication | Familial hypercholesterolemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 7 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Simvastatin inhibits HMG-CoA reductase, which lowers cholesterol synthesis in the liver. The liver responds by increasing LDL receptors, so blood LDL-C falls. Familial hypercholesterolemia is a genetic condition in which LDL clearance is impaired, so lowering LDL-C is the central treatment goal.
The supplied data does not state the original indication, so the link to the new indication cannot be traced from the registration records. The prediction fits simvastatin’s known use, and the evidence pack itself notes that heterozygous disease is a labelled use. Statins alone are generally not enough for homozygous disease, which needs add-on therapy.
The pack also lists a closely related prediction, autosomal dominant hypercholesterolemia (score 99.36%), with the same mechanism and the same Proceed with Guardrails outcome.
Clinical Trial Evidence
Many of the 19 trials study other drugs, such as alirocumab and colesevelam, with simvastatin as background therapy at most. The table lists the ten most relevant trials, which involve simvastatin directly or as a named background statin. No SANCTR or PACTR identifiers were supplied.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE: ezetimibe plus high-dose simvastatin vs simvastatin alone on carotid atherosclerosis in heterozygous FH |
| NCT00129402 | Phase 3 | Completed | 248 | Ezetimibe with simvastatin vs simvastatin alone in adolescents (10-17 years) with heterozygous FH |
| NCT00465088 | Phase 3 | Completed | 199 | SUPREME: niacin ER/simvastatin vs atorvastatin on HDL-C in hyperlipidemia or mixed dyslipidemia (not FH-specific) |
| NCT00654446 | Phase 3 | Completed | 442 | Renal effects of rosuvastatin vs simvastatin in Type IIa/IIb dyslipidaemia, including heterozygous FH |
| NCT03885921 | Phase 3 | Completed | 44 | Long-term safety of ezetimibe added to atorvastatin or simvastatin in homozygous FH (up to 24 months) |
| NCT03884452 | Phase 3 | Completed | 50 | Efficacy and safety of ezetimibe added to atorvastatin or simvastatin in homozygous FH |
| NCT00145574 | Phase 4 | Completed | 194 | Colesevelam in children with heterozygous FH on stable statins (including simvastatin) or treatment-naive |
| NCT01070966 | N/A | Completed | 2,089 | Post-marketing survey of ezetimibe/simvastatin (Vytorin) in usual practice |
| NCT00475826 | N/A | Unknown | Not listed | Chylomicron metabolism and subclinical atherosclerosis in heterozygous FH on statin plus ezetimibe |
| NCT01414192 | N/A | Completed | 3,215 | French cohort on ezetimibe alone or with a statin, for cardiovascular disease simulation models |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18376000 | 2008 | RCT | N Engl J Med | ENHANCE: simvastatin with or without ezetimibe in FH, measuring progression of atherosclerosis |
| 31696945 | 2019 | Systematic review | Cochrane Database Syst Rev | Statins for children with familial hypercholesterolemia |
| 27417002 | 2016 | Cohort/meta-analysis | J Am Coll Cardiol | Statin-induced reduction of coronary artery disease events and mortality in heterozygous FH |
| 11383320 | 2001 | Comparative study | Nutr Metab Cardiovasc Dis | Atorvastatin vs simvastatin for LDL-C goal attainment in heterozygous FH |
| 35629051 | 2022 | Cohort | J Clin Med | Simvastatin 10 mg in 13 children with FH vs diet only: effects on cellular immunity |
| 15794711 | 2005 | Review | Expert Opin Drug Saf | Benefits and risks of simvastatin in FH |
| 12908847 | 2003 | Review | Drug Saf | Benefits and risks of simvastatin in FH, with emphasis on long-term safety |
| 41824552 | 2026 | Guideline | Circulation | 2026 ACC/AHA multisociety dyslipidemia guideline, replacing the 2018 cholesterol guideline |
| 28437620 | 2017 | Guideline | Endocr Pract | AACE/ACE guidelines for dyslipidemia management and cardiovascular prevention |
| 18638604 | 2008 | Commentary | Am J Cardiol | Critique of how the ENHANCE surrogate endpoint should be interpreted |
South Africa Market Information
Seven SAHPRA registrations were found; the five supplied are shown. Approved indication text and EML status were not included in the supplied records.
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 36/7.5/0213 | Lipidex | Tablet |
| Reg. No. 37/7.5/0336 | Aspen simvastatin | Tablet |
| Reg. No. 38/7.5/0335 | Mylan simvastatin | Tablet |
| Reg. No. 41/7.5/0391 | Choleste | Tablet |
| Reg. No. A40/7.5/0399 | Roltesim 10 | Film-coated tablet (Fct) |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 trials involve simvastatin in familial hypercholesterolemia, and the mechanism is direct. The prediction largely confirms an established use rather than a new one. The other predicted indications (brain stem infarction, HIV, ABri amyloidosis and others) have little or no supporting evidence and are on Hold.
To proceed, the following is needed:
- The SAHPRA package insert (warnings, contraindications and approved indications), which is a blocking gap before safety screening.
- Confirmation of the familial hypercholesterolemia indication against the SA label.
- Age-appropriate dosing for paediatric and adolescent patients.
- Monitoring for myopathy and hepatic effects, and adherence to the label’s high-dose restriction.
- A check for CYP3A4 interactions. Boosted protease inhibitors and cobicistat raise simvastatin exposure and the risk of rhabdomyolysis, which matters in South Africa’s large HIV population.
- Mechanism of action data from DrugBank, to complete the mechanism analysis.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.